Replies to post #23 on CureVac B.V. (CVAC)

[Fezziwig2008]

“What makes CureVac different from the rivals in this race is dosage. The biotech is testing single-digit micrograms — 2, 4, 6 and 8 — in Phase I. And Haas says that the added potency of their vaccine should make it effective at extremely low dosing, something that would allow them to go further without scaling up like the high-dosage vaccines that are in development now.

CVAC has a GMP3 facility producing vaccine at risk. And Haas says they plan to add a group of additional GMP3 facilities in Q2 of next year, likely clustered together, which can produce hundreds of millions of doses for delivery in 2021, as they boot up a new GMP4 facility to handle the large production quantities for future use of their mRNA products — which extend into a variety of areas, including oncology.”